Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals
2018-003921-27Phase 2Active
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Doravirine concentration in seminal plasma and cervicovaginal fluid at week 8. Started Apr 2019; status: active.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-003921-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003921-27.